The Supreme Court has intervened in a case that threatens access to mifepristone, a medication used in roughly half of all U.S. abortions. A lower appeals court attempted to restrict telemedicine distribution of the drug, limiting how women can obtain medication abortions nationwide.
Legal briefs have been filed with the high court, setting the stage for a decision that will determine whether Americans can access abortion pills through telehealth services. The case stems from a challenge to FDA approval and regulations governing mifepristone's distribution, which currently allows doctors to prescribe the drug remotely and mail it to patients.
The appeals court ruling would have dramatically curtailed this access by requiring in-person doctor visits and pharmacy pickups. Such restrictions would eliminate a major pathway for abortion access, particularly in rural areas and states with limited abortion providers.
Pro-choice groups argue that restricting telemedicine access violates the FDA's scientific findings on mifepristone's safety and represents an unprecedented judicial override of drug approval decisions. They contend the lower court overstepped its authority by substituting its judgment for the FDA's expertise.
Anti-abortion advocates counter that courts should scrutinize any abortion procedure, including medication abortion, and argue the FDA was incorrect to ease distribution restrictions in 2023.
The timing places this question directly before the Supreme Court as the 2024 presidential campaign intensifies. Abortion remains a defining issue after the Court overturned Roe v. Wade in 2022, giving states power to ban abortion entirely. This case focuses narrowly on federal access to a specific drug rather than state abortion bans, but the outcome will reshape access for millions of women across the country.
A decision is expected by summer 2024. The Court's composition, with its 6-3 conservative majority, adds uncertainty to abortion rights advocates' prospects.
THE BOTTOM LINE: